Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
To investigate the possibility of intranasal immunization with an acellular pertussis vaccine, groups of mice were administered intranasally with aluminium-non-adsorbed pertussis toxoid (PTd; 0.5 or 5 microg) and formalin-treated filamentous hemagglutinin (fFHA; 5 microg) with and without recombinant cholera toxin B subunit (rCTB; 10 microg) as a mucosal adjuvant. At a low concentration of PTd, the following things became clear: (1) earlier and higher elevation of serum anti-PTd and anti-FHA IgG antibody titres in the presence of rCTB than in its absence, (2) higher serum anti-PTd and anti-FHA IgG antibody titres than 200 and 100 ELISA units ml(-1) (EU ml(-1)) in all mice, respectively, in the presence of rCTB, which were obtained by calibration against a reference anti-pertussis mouse serum, and (3) in an intranasal challenge experiment with Bordetella pertussis, slightly more rapid elimination of the bacteria from the lungs of mice intranasally immunized in the presence of rCTB, suggesting the effectiveness of rCTB as a mucosal adjuvant. However, irrespective of rCTB and dose of PTd, mice which were immunized four times and sacrificed on day 35 developed high levels of anti-PTd serum IgG antibodies, high or moderate levels of anti-FHA serum IgG antibodies and mucosal anti-PTd IgA antibodies in the lungs; only a slight or no increase of anti-FHA mucosal IgA antibodies was observed in the lung. These facts suggested the immunogenicity and mucosal adjuvanticity of PTd, and therefore, the mucosal adjuvanticity of rCTB seemed to be inconspicuous. Moreover, the addition of rCTB induced higher anti-PTd serum IgE antibody responses than no addition of it depending on dose of PTd. These results show that dose of PTd included in an acellular pertussis vaccine had better be low as possible and the addition of rCTB may not be always necessary in case of this nasal vaccine alone unlike tetanus and diphtheria toxoids and hepatitis B virus vaccine reported before.
Isaka
Masanori
M
Department of Microbiology, Nagoya City University Medical School, Mizuho-ku, Nagoya 467-8601, Japan.
Yasuda
Yoko
Y
Taniguchi
Tooru
T
Kozuka
Satoshi
S
Matano
Keiko
K
Maeyama
Jun-ichi
J
Morokuma
Kazunori
K
Ohkuma
Kunio
K
Goto
Norihisa
N
Tochikubo
Kunio
K
D018829:Adhesins, Bacterial / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000235:genetics; D001886:Bordetella pertussis / Q000276:immunology*; D002772:Cholera Toxin / Q000276:immunology*; D005260:Female; D005557:Formaldehyde; D006388:Hemagglutinins / Q000276:immunology*; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000096:biosynthesis* / Q000276:immunology; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000235:genetics; D007413:Intestinal Mucosa / Q000276:immunology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology*; D010567:Pertussis Vaccine / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D014121:Toxoids / Q000276:immunology*; D014611:Vaccination; D022282:Vaccines, Acellular / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology; D014621:Vagina / Q000276:immunology; D010566:Virulence Factors, Bordetella / Q000276:immunology*
D018829:Adhesins, Bacterial; D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D006388:Hemagglutinins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D011994:Recombinant Proteins; D014121:Toxoids; D022282:Vaccines, Acellular; D017778:Vaccines, Combined; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C051093:pertussis toxoid; D005557:Formaldehyde; D002772:Cholera Toxin